2018-19 Section 7-Neoplastic and Inflammatory Diseases of the Head and Neck eBook

Molecular Testing for Thyroid Nodules/Roth et al

14. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagno- sis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012 23;367:705-715. 15. Cancer Genome Atlas Research Network. Integrated genomic charac- terization of papillary thyroid carcinoma. Cell. 2014;159:676-690. 16. Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer . 2014;120:3627-3634. 17. Nikiforov YE, Carty SE, Chiosea SI, et al. Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thy- roid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology. Thyroid . 2015;25:1217-1223. 18. Nikiforova MN, Wald AI, Roy S, et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab . 2013;98:E1852-E1860. 19. Nikiforova MN, Chiosea SI, Nikiforov YE. MicroRNA expression profiles in thyroid tumors. Endocr Pathol . 2009;20:85-91. 20. Benjamin H, Schnitzer-Perlman T, Shtabsky A, et al. Analytical validity of a microRNA-based assay for diagnosing indeterminate thyroid FNA smears from routinely prepared cytology slides. Cancer Cytopathol . 2016;124:711-721. 21. Labourier E, Shifrin A, Busseniers AE, et al. Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytol- ogy. J Clin Endocrinol Metab . 2015;100:2743-2750. 22. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologi- cally indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab . 2011;96:3390-3397. 23. Lithwick-Yanai G, Dromi N, Shtabsky A, et al. Multicentre valida- tion of a microRNA-based assay for diagnosing indeterminate thy- roid nodules utilising fine needle aspirate smears [published online head of print October 26, 2016]. J Clin Pathol . doi: 10.1135/jclin- path-2016-204089. 24. Najafian A, Noureldine S, Azar F, et al. RAS mutations and RET/ PTC and PAX8/PPAR-gamma chromosomal rearrangements are also prevalent in benign thyroid lesions: implications thereof and a sys- tematic review. Thyroid . 2017;27:39-48. 25. Al-Quarayshi Z, Deniwar A, Thethi T, et al. Association of malig- nancy prevalence with test properties and performance of the gene expression classifier in indeterminate thyroid nodules [published online ahead of print December 15, 2016]. JAMA Otolaryngol Head Neck Surg . doi: 10.1001/jamaoto.2016.3526. 26. Yip L, Wharry LI, Armstong M. A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg . 2014;260:163-168. 27. Kloos RT, Monroe RJ, Traweek ST, Lanman RB, Kennedy GC. A genomic alternative to identify medullary thyroid cancer preopera- tively in thyroid nodules with indeterminate cytology. Thyroid . 2016;26:785-793. 28. Santhanam P, Khthir R, Gress T, et al. Gene expression classifier for the diagnosis of indeterminate thyroid nodules: a meta-analysis [serial online]. Med Oncol . 2016;33:14. 29. Samulski TD, LiVolsi VA, Wong LQ, Baloch Z. Usage trends and performance characteristics of a “gene expression classifier” in the management of thyroid nodules: an institutional experience. Diagn Cytopathol . 2016;44:867-873. 30. Villabona CV, Mohan V, Arce KM, et al. Utility of ultrasound ver- sus gene expression classifier in thyroid nodules with atypia of unde- termined significance. Endocr Pract . 2016;22:1199-1203. 31. Chaudhary S, Hou Y, Shen R, Hooda S, Li Z. Impact of the Afirma gene expression classifier result on the surgical management of thy- roid nodules with category III/IV cytology and its correlation with surgical outcome. Acta Cytol . 2016;60:205-210. 32. Wu JX, Young S, Hung ML, et al. Clinical factors influencing the performance of gene expression classifier testing in indeterminate thyroid nodules. Thyroid . 2016;26:916-922. 33. Labourier E. Utility and cost-effectiveness of molecular testing in thyroid nodules with indeterminate cytology. Clin Endocrinol (Oxf) . 2016;85:624-631.

34. Abeykoon JP, Mueller L, Dong F, Chintakuntlawar AV, Paludo J, Mortada R. The effect of implementing gene expression classifier on outcomes of thyroid nodules with indeterminate cytology. Horm Cancer . 2016;7:272-278. 35. Londero SC, Jespersen ML, Krogdahl A, et al. gene-expression classi- fier in papillary thyroid carcinoma: validation and application of a classifier for prognostication. Study from the Danish Thyroid Cancer Group–DATHYRCA (part of the DAHANCA organization). Anti- cancer Res . 2016;36:749-756. 36. Sipos JA, Blevins TC, Shea HC, et al. Long-term nonoperative rate of thyroid nodules with benign results on the Afirma gene expression classifier. Endocr Pract . 2016;22:666-672. 37. Noureldine SI, Olson MT, Agrawal N, Prescott JD, Zeiger MA, Tufano RP. Effect of gene expression classifier molecular testing on the surgical decision-making process for patients with thyroid nod- ules. JAMA Otolaryngol Head Neck Surg . 2015;141:1082-1088. 38. Celik B, Whetsell CR, Nassar A. Afirma GEC and thyroid lesions: an institutional experience. Diagn Cytopathol . 2015;43:966-970. 39. Wu JX, Lam R, Levin M, Rao J, Sullivan PS, Yeh MW. Effect of malig- nancy rates on cost-effectiveness of routine gene expression classifier test- ing for indeterminate thyroid nodules. Surgery . 2016;159:118-126. 40. Yip L, Nikiforova MN, Yoo JY, et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg. 2015;262:519-525; discussion 525-525. 41. Witt RL. Outcome of thyroid gene expression classifier testing in clinical practice. Laryngoscope . 2016;126:524-527. 42. Wong KS, Angell TE, Strickland KC, et al. Noninvasive follicular variant of papillary thyroid carcinoma and the Afirma gene- expression classifier. Thyroid . 2016;26:911-915. 43. Lastra RR, Pramick MR, Crammer CJ, LiVolsi VA, Baloch ZW. Implications of a suspicious Afirma test result in thyroid fine-needle aspiration cytology: an institutional experience. Cancer Cytopathol . 2014;122:737-744. 44. Brauner E, Holmes BJ, Krane JF, et al. Performance of the Afirma gene expression classifier in Hurthle cell thyroid nodules differs from other indeterminate thyroid nodules. Thyroid . 2015;25:789-796. 45. McIver B, Castro MR, Morris JC, et al. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indetermi- nate thyroid nodules. J Clin Endocrinol Metab . 2014;99:4069-4077. 46. Krane JF. Lessons from early clinical experience with the Afirma gene expression classifier. Cancer Cytopathol . 2014;122:715-719. 47. Harrell RM, Bimston DN. Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indetermi- nate thyroid cytology. Endocr Pract . 2014;20:364-369. 48. Kloos RT, Reynolds JD, Walsh PS, et al. Does addition of BRAF V600E mutation testing modify sensitivity of the Afirma gene expression classifier in cytologically indeterminate thyroid nodules? J Clin Endocrinol Metab . 2013;98:E761-E768. 49. Alexander EK, Schorr M, Klopper J, et al. Multicenter clinical expe- rience with the Afirma gene expression classifier. J Clin Endocrinol Metab . 2014;99:119-125. 50. Duick DS, Klopper JP, Diggans JC, et al. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine- needle aspiration cytopathology. Thyroid . 2012;22:996-1001. 51. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010. 52. Angell TE, Frates MC, Medici M, et al. Afirma benign thyroid nod- ules show similar growth to cytologically benign nodules during fol- low-up. J Clin Endocrinol Metab . 2015;100:E1477-E14583. 53. Zhu QL, Faquin WC, Samir AE. Relationship between sonographic characteristics and Afirma gene expression classifier results in thyroid nodules with indeterminate fine-needle aspiration cytopathology. AJR Am J Roentgenol . 2015;205:861-865. 54. Sohn SY, Park WY, Shin HT, et al. Highly concordant key genetic alterations in primary tumors and matched distant metastases in dif- ferentiated thyroid. Thyroid . 2016;26:672-682. 55. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocri- nol Metab . 2005;90:6373-6379.

Cancer

March 1, 2018

151